Investigation Launched for MoonLake Immunotherapeutics Investors
PHILADELPHIA — A significant development has arisen involving MoonLake Immunotherapeutics (NASDAQ: MLTX). The national plaintiffs' law firm Berger Montague PC has initiated an investigation into claims on behalf of investors affected by a class action lawsuit targeting the company. This investigation is centered around allegations accusing MoonLake of disseminating false and misleading information regarding its primary drug candidate, sonelokimab (SLK).
Background on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology firm located in Zug, Switzerland. The firm focuses on innovative drug developments aimed at treating various skin conditions. However, the recent filing has raised questions about the credibility and efficacy of their primary product, SLK, which has come under scrutiny following the announcement of its Phase 3 clinical trial results.
Allegations Against the Company
According to the lawsuit, MoonLake executives allegedly promoted SLK’s unique Nanobody structure as offering superior advantages compared to traditional therapies like FDA-approved BIMZELX. The complaint claims these assertions were misleading, leading investors to believe in the product’s effectiveness based on unfounded claims.
Phase 3 Trial Results and Market Reaction
The turning point occurred on September 28, 2025, when MoonLake released the results of its Phase 3 clinical trial. The findings reportedly indicated that SLK did not meet the expected efficacy benchmarks set by BIMZELX. Analysts quickly labeled the trial results as disastrous, resulting in a staggering drop of almost 90% in stock value, equivalent to a loss of $55.75 per share in one trading day. Such a plummet signals significant investor concern and potential financial ramifications for those involved.
Investor Actions and Rights
For investors who purchased MoonLake securities during the class action period from March 10, 2024, to September 29, 2025, there is an opportunity to participate in this legal action. Interested parties must seek appointment as lead plaintiff representatives by a specified deadline. Understanding these rights and the implications of the lawsuit is crucial for affected investors.
How to Get Involved
Individuals interested in learning more about their rights in regard to this investigation into MoonLake Immunotherapeutics are encouraged to take action promptly. Information on the claim process is vital for those seeking accountability from the firm.
About Berger Montague
Founded in 1970, Berger Montague has built a reputation as a leading firm in the realm of securities class action litigation. With offices strategically located across major cities, the firm has dedicated decades to representing both individual and institutional investors. Their commitment to justice and advocacy for investors is evident in their extensive track record.
Contact Information for Inquiry
Those wishing to discuss their rights or learn more about the ongoing investigation into MoonLake can reach out directly to representatives at Berger Montague. Andrew Abramowitz serves as Senior Counsel at the firm and is available for inquiries.
Frequently Asked Questions
What prompted the investigation into MoonLake Immunotherapeutics?
The investigation was initiated after a class action lawsuit was filed, alleging the company made misleading statements about its drug candidate, SLK.
What are the specific allegations against MoonLake?
The allegations include false promotion of SLK's effectiveness and advantages over existing treatments, potentially misleading investors.
When did the damaging news about SLK emerge?
The critical information came to light following the release of Phase 3 clinical trial results on September 28, 2025.
How much did MoonLake's stock drop after the trial results?
The stock plummeted by nearly 90%, equating to a decrease of $55.75 per share, in reaction to the disappointing trial results.
How can investors participate in the class action lawsuit?
Investors who purchased during the specified period can seek appointment as a lead plaintiff representative by the established deadline to involve themselves in the class action.
